Hydrogen Composition for Mild Cognitive Impairment in ApoE ε4 Carriers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and preventive measures for mild cognitive impairment and dementia are inadequate, particularly for individuals with the ApoE ε4 genetic polymorphism, which is a significant risk factor for these conditions.
Innovation Solution
A composition comprising molecular or atomic hydrogen, administered as hydrogen water, hydrogen gas, or hydrogen-storing microparticles, is used to prevent or treat mild cognitive impairment and dementia, with a focus on ApoE ε4 allele carriers, enhancing cognitive function and reducing the risk of progression to dementia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antioxidant treatments are used for mild cognitive impairment or dementia, then general oxidative stress is reduced, but they are ineffective for ApoE ε4 allele carriers who have high risk of cognitive decline
Solution Approach 1:
The patent applies local quality by targeting hydrogen therapy specifically to ApoE ε4 allele carriers based on their genetic polymorphism. The treatment is customized according to the patient's genetic profile, providing localized effectiveness for this high-risk group rather than applying a universal antioxidant approach to all patients.
Solution Approach 2:
The patent utilizes parameter changes by introducing hydrogen (molecular or atomic) as a specific active ingredient with distinct chemical properties. Hydrogen's unique ability to selectively neutralize hydroxyl radicals and its solubility characteristics enable it to cross the blood-brain barrier and specifically protect neurons in ApoE ε4 carriers, changing the therapeutic parameter from general antioxidants to targeted hydrogen therapy.
2Reliability
If hydrogen water is administered to ApoE ε4 allele carriers, then cognitive function improves and progression to dementia is prevented, but the treatment requires long-term administration over 1 year or more
Solution Approach 1:
The patent applies preliminary action by administering hydrogen therapy during the mild cognitive impairment stage, before full dementia develops. This early intervention prevents progression to dementia by neutralizing oxidative stress and promoting neurogenesis in the prodromal stage, addressing the condition before it becomes irreversible.
Solution Approach 2:
The patent implements continuity of useful action through long-term hydrogen administration. The treatment requires consistent, continuous intake of hydrogen water or hydrogen gas over extended periods (1 year or more) to maintain protective effects against cognitive decline and prevent progression to dementia, emphasizing the need for sustained therapeutic action.
3Object-affected harmful factors
If hydrogen is used as an antioxidant, then general oxidative stress is reduced, but it does not specifically address the neurodegenerative mechanisms in Alzheimer's disease and mild cognitive impairment
Solution Approach 1:
The patent applies blessing in disguise by converting the harmful oxidative stress caused by ApoE ε4-related metabolism into a beneficial effect through hydrogen therapy. Hydrogen selectively neutralizes hydroxyl radicals and other reactive oxygen species generated by ApoE ε4 metabolism, transforming the harmful oxidative environment into a protected state that prevents neurodegeneration.
Solution Approach 2:
The patent uses hydrogen as an intermediary substance that mediates between ApoE ε4-related oxidative stress and neuronal protection. Hydrogen acts as a intermediary antioxidant that specifically targets and neutralizes harmful reactive oxygen species without disrupting normal cellular metabolism, bridging the gap between oxidative damage and neuroprotection in ApoE ε4 carriers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogen-based composition effectively prevents or treats mild cognitive impairment and dementia, particularly in ApoE ε4 allele carriers, by improving cognitive functions and reducing the decline of working memory, as evidenced by significant score improvements in cognitive assessment tests.
Implementation Method 1
hydrogen has recently been found to have various effects besides the conventional antioxidant capacity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
An object of the present invention is to provide a composition for prevention or treatment for mild cognitive impairment or dementia. The present invention is a composition for prevention or treatment for mild cognitive impairment or dementia, comprising hydrogen as an active ingredient.